Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants-Reference-Cited by-同舟云学术

Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants

Published:2021-12-24 Issue:6575 Volume:374 Page:1621-1626
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

McCallum Matthew¹^ORCID,Walls Alexandra C.¹^ORCID,Sprouse Kaitlin R.¹^ORCID,Bowen John E.¹^ORCID,Rosen Laura E.²^ORCID,Dang Ha V.¹^ORCID,De Marco Anna³^ORCID,Franko Nicholas⁴^ORCID,Tilles Sasha W.⁵^ORCID,Logue Jennifer⁴^ORCID,Miranda Marcos C.¹⁶,Ahlrichs Margaret¹⁶^ORCID,Carter Lauren¹⁶^ORCID,Snell Gyorgy²^ORCID,Pizzuto Matteo Samuele³^ORCID,Chu Helen Y.⁴^ORCID,Van Voorhis Wesley C.⁵^ORCID,Corti Davide³^ORCID,Veesler David¹⁷^ORCID

Affiliation:

1. Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.

2. Vir Biotechnology, San Francisco, CA 94158, USA.

3. Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.

4. Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.

5. Center for Emerging and Re-emerging Infectious Diseases, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.

6. Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.

7. Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.

Abstract

How the Delta variant evades defenses In the course of the COVID-19 epidemic, variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge, some of which evade immunity or increase transmission. In late 2020, the Delta and Kappa variants were detected, and the Delta variant became globally dominant by June 2021. McCallum et al . show that vaccine-elicited serum-neutralizing activity is reduced against these variants. Based on biochemistry and structural studies, the authors show that mutations in the domain that binds the ACE2 receptor abrogate binding to some monoclonal antibodies but do not improve ACE2 binding, suggesting that they emerged to escape immune recognition. Remodeling of the N-terminal domain allows the variants to escape recognition by most neutralizing antibodies that target it. The work could guide the development of next-generation vaccines and antibody therapies. —VV

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference103 articles.

1. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

2. Detection of a SARS-CoV-2 variant of concern in South Africa

3. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

4. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

5. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Cited by 197 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Paradigm of immune dysregulation in coronavirus disease-2019 infection;Exploration of Immunology;2024-01-31

2. Adaptive advantage of deletion repair in the N-terminal domain of the SARS-CoV-2 spike protein in variants of concern;2024-01-24

3. What makes SARS‐CoV‐2 unique? Focusing on the spike protein;Cell Biology International;2024-01-23

4. Studies on Human-Coronavirus protein-protein interaction network from the perspective of viral adaptation in a novel host;2024-01-15

5. Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy;Frontiers in Immunology;2024-01-08